Licensing status

Publication and contact information

Infectious disease

Dengue fever

Dengue virus envelope protein E (DENV_gp1)

In vitro studies have identified residues of the dengue virus envelope protein that could be targeted to treat dengue fever. In cultured human cells, infection with dengue virus clones containing point mutations in each of 390 DENV_gp1 ectodomain residues identified 18 residues required for viral infectivity that did not structurally impair the protein. Mapping the residues to seven known conformational folding structures of the protein showed that the critical residues were located near the protein fusion loop, a conserved region at the interface of envelope protein domain interactions. Next steps include evaluating how mAbs targeting envelope protein interact with the critical residue regions.
Altravax Inc. has a vaccine against DENV_gp1 in preclinical testing for dengue fever.

SciBX 6(46); doi:10.1038/scibx.2013.1323
Published online Dec. 5, 2013

Patents filed by Integral Molecular Inc. covering the mutagenesis method to create the mutations and the envelope protein-targeted mAbs; licensing status undisclosed

Christian, E.A. et al. Proc. Natl. Acad. Sci. USA; published online
Oct. 24, 2013;
Contact: Benjamin J. Doranz, Integral Molecular Inc.,
Philadelphia, Pa.